2012 Herbert and Maxine Block Memorial Lectureship Award
Congratulations to Levi Garraway, MD, PhD, on becoming the 19th recipient of the Herbert and Maxine Block Memorial Lectureship Award for Distinguished Achievement in Cancer.
Levi Garraway, MD, PhD, is an associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, and a senior associate member of the Broad Institute.
An internationally renowned oncologist and researcher, Dr. Garraway leads an investigative team in cancer genomics at Dana-Farber and the Broad Institute, and he is co-leader of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center. He has made significant research contributions in cancer genomics, drug resistance and genomics-driven (or “personalized”) cancer medicine. He published the first gene-sequencing studies of aggressive prostate cancer and has led other major gene-sequencing initiatives in prostate cancer, melanoma, and head and neck cancers.
Dr. Garraway’s scholarly work has consistently been published in the world’s top scientific journals. In recognition of his contributions, he has been the recipient of several awards and honors. In 2009, he was inducted into the American Society for Clinical Investigation.
Previous Award Recipients (Note: affiliations listed were those held at time of award.)
- Samuel Broder, MD, director of the National Cancer Institute
- Robert C. Young, MD, president, Fox Chase Cancer Center (Philadelphia)
- Bert Vogelstein, MD, professor of Oncology and Molecular Biology/Genetics, Johns Hopkins University School of Medicine (Baltimore)
- Judah Folkman, MD, Andrus Professor of Pediatric Surgery, Harvard Medical School, Children’s Hospital (Boston)
- V. Craig Jordan, PhD, DSc, professor of Pharmacology and director of the Breast Cancer Research Program at the Robert H. Lurie Cancer Center, Northwestern University Medical Center (Chicago)
- Barbara K. Rimer, DrPH, director, Division of Cancer Control and Population Science, National Cancer Institute
- Richard D. Klausner, MD, director of the National Cancer Institute
- John Potter, MD, PhD, director of the Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center (Seattle)
- Donald Coffey, PhD, professor of Urology, Oncology, Pathology, Pharmacology and Molecular Science, Johns Hopkins University School of Medicine (Baltimore)
- David Botstein, PhD, professor and chair, Department of Genetics, Stanford University School of Medicine (Palo Alto, California)
- Daniel Von Hoff, MD, professor of Medicine, Molecular and Cellular Biology, and Pathology; director, Arizona Cancer Center, University of Arizona (Tucson)
- Carlo Croce, MD, director of the Kimmel Cancer Institute/Kimmel Cancer Center at Jefferson Medical College, Thomas Jefferson University (Philadelphia); subsequently joined Ohio State where he serves as director of the Human Cancer Genetics Program
- Larry Norton, MD, medical oncologist leader of Breast Disease Management Team at Memorial Sloan-Kettering Cancer Center (New York)
- C. Norman Coleman, MD, director, Radiation Oncology Services Program, National Cancer Institute
- Steven Rosenberg, MD, PhD, chief of Surgery, National Cancer Institute; professor of Surgery, George Washington University School of Medicine and Health Sciences
- George Klein, MD, PhD, professor emeritus and research group leader, Microbiology and Tumor Biology Center, Karolinska Institute (Stockholm, Sweden)
- Kathleen M. Foley, MD, attending neurologist, Pain and Palliative Care Service, Memorial Sloan-Kettering Cancer Center; professor, Neurology, Neuroscience and Clinical Pharmacology, Weill Medical College, Cornell University (New York)
- Bruce A. Chabner, MD, professor, Department of Medicine, Harvard Medical School; director, clinical research, Massachusetts General Hospital